A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

Multiple Myeloma Clinical Trial

— iStopMM  

Official title:

Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03815279
• Other study ID #: LSH-17-001
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: June 24, 2019
• Est. completion date: January 2028

Study information

• Verified date: August 2019
• Source: Landspitali University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib.

Description:

This is an open label, single center, phase II study assessing the efficacy of treating patients with intermediate-risk smoldering myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide and treating patients with high risk SMM and active multiple myeloma (MM) with combinational therapy with dexamethasone, lenalidomide and carfilzomib. Patients that are eligible for this study are participants in the IstopMM study (ClinicalTrials.gov number, NCT03327597) that are diagnosed with intermediate or high-risk SMM or active MM.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 80
• Est. completion date: January 2028
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants that are diagnosed with MM, high- or intermediate-risk SMM in the iStopMM study will be invited to participate in this study. Each patient must meet all the following inclusion criteria to be enrolled in the study:

1. Age more than 18 years.

2. Active MM or

3. Smoldering myeloma, which is untreated, as defined by: Measurable M spike OR pathological FLC ratio AND bone marrow PC% > 10%

4. The following laboratory values obtained = 30 days prior to registration

• Calculated creatinine clearance = 30mL/min (using CKD-EPI equation)

• Absolute neutrophil count (ANC) > 1000/mm3

• Platelet count > 75000/mm3

• Hemoglobin = 8.0 g/dL

• Total bilirubin = 1.5 x ULN

• ALT and AST = 3 x ULN

5. Measurable disease as defined by at least one of the following:

• Serum monoclonal protein > 1.0g/L

• > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis

• Serum immunoglobulin free light chain = 10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio

6. Prior therapy for the treatment of solitary plasmacytoma is permitted, but >7 days should have elapsed from the last day of radiation. NOTE: Prior therapy with clarithromycin, DHEA, anakinra, pamidronate or zoledronic acid is permitted. Any additional agents not listed must be approved by the Principal Investigator.

7. ECOG performance status 0, 1 or 2

8. Negative pregnancy test done =7 days prior to C1D1, for women of childbearing potential only.

9. Willing to follow strict birth control measures as outlined in the protocol.

10. Female subjects: If they are of childbearing potential, agree to one of the following:

Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of trial drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program (appendix 1), if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

11. Male subjects: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: Agree to practice effective barrier contraception during the entire trial treatment period and through 90 days after the last dose of trial drug, OR Must also adhere to the guidelines of any treatment-specific pregnancy prevention program (appendix 1), if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). Willing to return to enrolling institution for follow-up during the Active Treatment Phase of the trial. Agree not to donate sperm for at least 90 days after the last dose of carfilzomib

12. Willing to provide samples for planned research

13. Life expectancy > 6 months

Exclusion Criteria:

1. MGUS or low-risk smoldering myeloma.

2. Diagnosed or treated for another malignancy = 2 years before trial enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. NOTE: Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

3. If any of the following exist at screening, subject will not be eligible for trial because this trial involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: Pregnant women Nursing women Men or women of childbearing potential who are unwilling to employ adequate contraception (per protocol)

4. Other co-morbidity which would interfere with subject's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease

5. Other concurrent chemotherapy, or any ancillary therapy considered investigational.

NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment.

6. Peripheral neuropathy > Grade 3 on clinical examination or grade 2 with pain within 30 days prior to C1D1.

7. Major surgery =14 days prior to C1D1.

8. Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past 6 months. Note: Prior to trial entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.

9. Known human immunodeficiency virus (HIV) positive.

10. Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.

11. Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.

12. Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products.

Known allergies, hypersensitivity, or intolerance to trial drugs.

13. Inability to comply with protocol/procedures.

14. LVEF < 40% for patients treated with carfilzomib.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Smoldering Multiple Myeloma

Intervention

Drug:
• Carfilzomib
Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
• Lenalidomide
Lenalidomide PO once daily on days 1-21 of a 28 day cycle
• Dexamethasone
Dexamethasone will be administered weekly

Locations

Country	Name	City	State
Iceland	Landspitali University Hospital	Reykjavík

Sponsors (5)

Lead Sponsor	Collaborator
Landspitali University Hospital	Amgen, Celgene, Memorial Sloan Kettering Cancer Center, University of Iceland

Country where clinical trial is conducted

Iceland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of MRD negativity	Minimal residual disease (MRD) as determined VDJ sequencing	36 months after study enrollment
Secondary	Progression free survival	Rates of progression free survival with progression being determined by IMWG response criteria	Up until 3 years after treatment
Secondary	Overall survival	Overall survival as determened by the Icelandic National Cause of Death Registry	Up until 3 years after treatment